A contemporary overview of Cutaneous melanoma, co-authored by MIA, has been published in The Lancet, one of the world's leading medical journals.
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.
Read more about how the MIA team continues to play a leading role in pushing melanoma research boundaries at ASCO23, the world's leading clinical oncology conference.
Combined immunotherapy ipilimumab and nivolumab is now available on the PBS for all advanced melanoma patients.
In a world-first, an early phase trial of an mRNA personalised cancer vaccine has shown promising results for preventing melanoma recurrence in patients with resected high-risk melanoma (stage III and IV).
Read more about the five MIA researchers named on the Clarivate list of Highly Cited Researchers 2022.
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.
Diets low in fibre and omega-3 fatty acids linked to poorer response to immunotherapy.
Sun Safe Sport initiative and modernised awareness campaign critical to preventing melanoma which claims more lives than our annual road toll.